Despite the availability of consensus recommendations by ASCO and CAP, for determination of tissue HER2 expression levels in breast cancer (updated most recently in 2016)[35] and the availability of FDA-approved testing methods/kits [16], compliance has been questioned. This evidence concerns the gene ERBB2 and breast carcinoma.